Printer Friendly

BARR REINTRODUCES ANTI-ANXIETY DRUG

 POMONA, N.Y., Dec. 10 /PRNewswire/ -- Barr Laboratories, Inc. (AMEX: BRL), announced today the reintroduction of Hydroxyzine Pamoate Capsules, USP 100mg, a generic equivalent to Pfizer's Vistaril(R).
 Barr and the FDA agree that the additional studies completed for Hydroxyzine Pamoate Capsules 100mg satisfy the FDA's validation requirements. Hydroxyzine Pamoate Capsules 100mg brings the number of products reintroduced under Barr Laboratories' revalidation program to a total of nine.
 Barr reintroduced Hydroxyzine Pamoate 25mg earlier this year. The two products, Hydroxyzine Pamoate 25mg and 100mg, when last marketed together, accounted for approximately $1 million in sales on an annualized basis.
 Hydroxyzine Pamoate is used to treat symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
 Barr Laboratories is a manufacturer of a broad range of generic pharmaceutical products with manufacturing facilities located in Northvale, N.J., and Pomona.
 -0- 12/10/93
 /CONTACT: Harold Cohen of Barr Laboratories, 914-353-8444/
 (BRL)


CO: Barr Laboratories, Inc. ST: New York IN: MTC SU: PDT

WB-TW -- NY050 -- 2638 12/10/93 12:38 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1993
Words:182
Previous Article:ITW DIRECTORS DECLARE QUARTERLY DIVIDEND
Next Article:GATX ELECTS NEW BOARD MEMBER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters